https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

HIV Cure Research Strategy for Women: Where Are We? Img
USCA (U.S. Conference on AIDS)

HIV Cure Research Strategy for Women: Where Are We?

Women are drastically underrepresented in HIV cure research studies. The need for a cure is critical, but will the search for HIV cure strategies include women?

MK-8591: Further Compelling Early Results for Both Treatment and Prevention Img
IAS (International AIDS Society) Conference

MK-8591: Further Compelling Early Results for Both Treatment and Prevention

Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.

Understanding Exactly How the 'Berlin Patient' Was Cured Img

Understanding Exactly How the 'Berlin Patient' Was Cured

A report on three other cases of HIV-infected individuals receiving stem cell transplants indicates the likely role that CCR5 mutation plays in HIV remission or cure.

HIV Pipeline Drugs: IAS 2017 Update Img
IAS (International AIDS Society) Conference

HIV Pipeline Drugs: IAS 2017 Update

A review of HIV drugs in development that summarizes the most exciting new research over the previous year.

Scientists Hone in on the Best Way to Expose HIV Hidden in the Viral Reservoir, a Crucial Step Toward an Eventual Cure Img

Scientists Hone in on the Best Way to Expose HIV Hidden in the Viral Reservoir, a Crucial Step Toward an Eventual Cure

Researchers at the University of North Carolina identified a better dosing strategy for a drug that exposes HIV hiding inside the body's viral reservoir, according to a new study.

Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF Img
IAS (International AIDS Society) Conference

Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF

Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.

HIV Remission News From IAS 2017 Img
IAS (International AIDS Society) Conference

HIV Remission News From IAS 2017

Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.

The Future of 2-Drug Regimens for People With HIV Img
Features

The Future of 2-Drug Regimens for People With HIV

Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. What can we expect in the future for two-drug regimens?

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort Img

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort

Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.

Bictegravir/FTC/TAF: New Once-Daily Integrase-Based Fixed-Dose Combination Submitted to U.S. FDA Img

Bictegravir/FTC/TAF: New Once-Daily Integrase-Based Fixed-Dose Combination Submitted to U.S. FDA

Gilead Sciences has submitted a new drug application to the U.S. FDA for a single tablet fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).